

ARCUS OVERVIEW

NYSE: RCUS



Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer

HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



Targets: CD73, HIF2a, A2a/2b, AXL



Targets: TIGIT, PD-1, CD39

Goal of **1-2** new molecules advancing into clinic each year



Accelerated P 1/2 signal-seeking & platform studies

DIVERSE PIPELINE WITH MULTIPLE "SHOTS ON GOAL"

7



Different molecules in clinic

Multiple



Registrational Phase 3 trials evaluating a differentiated, Fc-silent anti-TIGIT antibody domvanalimab

24-36



Months for potential approval & revenue generation

\$10B+



Addressable market opportunity in the U.S. based on expected drug treatable patient population

TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:
~\$1.7B

- Holds ~33% equity stake in Arcus
- 50/50 cost-sharing on studies within the joint development program
- Co-development / co-commercialization in the U.S.



STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING INTO 2027



~\$1.2B in pro forma cash, cash equivalents and marketable securities* as of 1/29/2024

* = unaudited cash, cash equivalents and marketable securities of \$866M as of December 31, 2023 adjusted to give effect to equity investment by Gilead of \$320M in January 2024

HQ & RESEARCH CAMPUSES IN BAY AREA



~600 employees

Learn more at investors.arcusbio.com

This summary is provided as of 1/29/2024. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com.